117
Safety of Two-Step Graded Challenges to Beta-Lactams Using a Single-Blinded Placebo-Controlled Protocol
Saturday, March 5, 2016
South Exhibit Hall H (Convention Center)
Melissa Iammatteo, MD, Denisa Ferastraoaru, MD MSc, Santiago Alvarez Arango, MD, Niharika Thota, MD, Ayobami Akenroye, MD, MPH, Elina Jerschow, M.D., M.Sc.
Rationale: Graded challenges are performed to exclude immediate hypersensitivity reactions.   We aimed to validate the safety of two-step graded challenges (test doses) by comparing the reaction rate of two-step challenges with placebos in patients with a negative skin test to beta-lactams.

Methods: We performed a five-year retrospective chart review of all patients who underwent single-blinded placebo-controlled two-step challenges to beta-lactams in an outpatient setting.  

Results: Between 2010 and 2015, 154 patients underwent 162 challenges to beta-lactams. The majority of patients was female (81.2%) with a mean age of 51.4 years (SE ±1.5). All challenges were preceded by negative skin testing and most (98%) were preceded by placebo. Reactions to placebo occurred in 11.3% of challenges (n=18) and to beta-lactams in 6.2% (n=10). Patients who reacted to placebos were female (100%, p=0.04) and more likely to have a history of multiple reported drug allergies: 4.6 (SE ±0.9) vs. 2.5 (SE ±0.5) drug allergies in those who reacted to medication (SE ±0.5) vs. 2.4 (SE ±0.1) drug allergies in those who had no reaction (p<0.01).  The majority of all reactions was mild and subjective (n=24/28, 86%) with spontaneous resolution (n= 25/28, 89%). Reactions to placebos included pruritus (n=12), sensation of throat tightness (n=2), and hives (n=1). Reactions to medications included pruritus (n=4), tingling (n=3), and fatigue (n=3). No anaphylactic reactions occurred.   

Conclusions: This study validates the safety of two-step challenges to beta-lactams. Since a greater number of reactions occurred to placebo rather than to beta-lactams, it is likely that some reactions are not due to drugs.